Key facts
- Cellergy Therapeutics’s last known valuation is $5.0M (Nov 2025).
- It has raised $3.5M; the latest was Early Stage VC ($3.5M) in Nov 2025.
- Notable investors include Fresh.Fund, ENKORE International Enterprises.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Cellergy Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellergy Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellergy Therapeutics
Operator of a biotechnology company intended to transform human health. The company is making a mitochondrial product for systemic repeated administration with fully matched allogeneic purified mitochondria, in IV administration for large systemic indications such as CNS, muscle degeneration, and aging, enabling patients to help energize cells, fight degenerative diseases and enhance healthy longevity.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2021
- Employees
- 6
- Website
- cellergy-bio.com/
- Ownership
- Privately Held (backing)
Cellergy Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellergy Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellergy Therapeutics in its N-PORT filings yet. We sweep new filings monthly.